Lates News

Citigroup analyst Vivek Agrawal said that the feasibility of President Trump's plan to lower prescription drug prices in the United States is still uncertain, but this news still poses a negative impact on overall Indian pharmaceutical stocks. A decrease of 30%-80% in prices typically applies to public healthcare systems such as federal insurance and Medicaid, but the specific scope of this potential executive order is not yet clear. Citigroup believes that the high drug prices in the United States are due in part to the insurance system and also reflect the profit margin of middlemen. Simply lowering the surface price may not truly solve this issue. Indian pharmaceutical companies involved in branded drugs/specialty drugs are most affected, while generic drug manufacturers are least affected. Sun Pharma fell by 3.1% and Aurobindo Pharma fell by 2.7%.